Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Healthcare Biotechnology
Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP... see more

Recent & Breaking News (TSXV:HEM)

Hemostemix Announces the Appointments of Loran Swanberg and Christina Wu, CPA, CGA

Newsfile April 9, 2020

Hemostemix Appoints the Honourable Sheila Copps, OC, PC, to Board of Advisors and Ratifies Thomas Smeenk as Chief Executive Officer

Newsfile April 7, 2020

Hemostemix Announces Closing of Second Tranche of Private Placement

Newsfile March 26, 2020

Hemostemix Announces Peter Lacey as Chairman of the Board of Directors

Newsfile March 19, 2020

Hemostemix Announces Dr. York Hsiang Joins Its Scientific Advisory Board

Newsfile March 16, 2020

Hemostemix Announces Corporate Update

Newsfile March 10, 2020

Hemostemix Announces Closing of First Tranche of Private Placement

Newsfile March 5, 2020

IIROC Trading Resumption - HEM

Canada NewsWire March 2, 2020

Hemostemix Announces Corporate Update

GlobeNewswire February 28, 2020

IIROC Trading Halt - HEM

Canada NewsWire February 28, 2020

Hemostemix Announces Corporate Update

GlobeNewswire February 25, 2020

Hemostemix Announces Financing Update and Secured Convertible Debenture Financing of Up to $2,000,000

GlobeNewswire February 19, 2020

Hemostemix Announces the Appointment of Dr. Ronnie Hershman to the Board of Directors and Provides a Corporate Update

GlobeNewswire February 10, 2020

Hemostemix Provides Corporate Update and Clarification

GlobeNewswire January 26, 2020

Hemostemix Announces Private Placement

GlobeNewswire January 2, 2020

Hemostemix Announces Corporate Update

GlobeNewswire December 11, 2019

IIROC Trading Resumption - HEM

Canada NewsWire December 3, 2019

Hemostemix Announces Appointment of Director and Postponement of Annual and Special Meeting

GlobeNewswire December 2, 2019

Hemostemix Announces Appointment of Director

GlobeNewswire November 29, 2019

IIROC Trading Halt - HEM

Canada NewsWire November 22, 2019